Ventrus Hits Trifecta in Pivotal VEN 307 Trial
By Marie Powers
Tuesday, May 15, 2012
Shares of Ventrus Biosciences Inc. (NASDAQ:VTUS) gained 14.8 percent Monday, closing at $12.58, after the company reported improvement in three measures of efficacy in a pivotal Phase III study of VEN 307 (diltiazem hydrochloride cream) in anal fissures.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.